News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,058 Results
Type
Article (42304)
Company Profile (436)
Press Release (671318)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208732)
Career Advice (2021)
Deals (36005)
Drug Delivery (104)
Drug Development (83578)
Employer Resources (173)
FDA (16430)
Job Trends (15095)
News (352787)
Policy (33079)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (85)
Alliances (50950)
ALS (94)
Alzheimer's disease (1427)
Antibody-drug conjugate (ADC) (139)
Approvals (16418)
Artificial intelligence (262)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (81)
Brain cancer (26)
Breast cancer (281)
Cancer (2270)
Cardiovascular disease (183)
Career advice (1688)
Career pathing (30)
CAR-T (152)
Cell therapy (432)
Cervical cancer (19)
Clinical research (67738)
Collaboration (864)
Compensation (530)
Complete response letters (24)
COVID-19 (2645)
CRISPR (42)
C-suite (244)
Cystic fibrosis (105)
Data (2164)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (268)
Diagnostics (6421)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87696)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115758)
Executive appointments (733)
FDA (17671)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (781)
Gene editing (109)
Generative AI (20)
Gene therapy (318)
GLP-1 (743)
Government (4499)
Grass and pollen (4)
Guidances (53)
Healthcare (19145)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (127)
Indications (29)
Infectious disease (2790)
Inflammatory bowel disease (142)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (95)
Interviews (311)
IPO (16781)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (492)
Leadership (17)
Legal (7986)
Liver cancer (74)
Lung cancer (321)
Lymphoma (152)
Machine learning (6)
Management (58)
Manufacturing (306)
MASH (68)
Medical device (13517)
Medtech (13522)
Mergers & acquisitions (19748)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (98)
Neuropsychiatric disorders (33)
Neuroscience (1982)
NextGen: Class of 2025 (6755)
Non-profit (4548)
Northern California (2650)
Now hiring (39)
Obesity (381)
Opinion (223)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (82)
Parkinson's disease (153)
Partnered (21)
Patents (232)
Patient recruitment (106)
Peanut (47)
People (58646)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21280)
Phase II (29891)
Phase III (22101)
Pipeline (1171)
Policy (144)
Postmarket research (2601)
Preclinical (9111)
Press Release (67)
Prostate cancer (107)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (399)
Real estate (6015)
Recruiting (66)
Regulatory (22715)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (139)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2293)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3761)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (33)
The Weekly (48)
United States (23210)
Vaccines (699)
Venture capitalists (43)
Weight loss (252)
Women's health (37)
Worklife (16)
Date
Today (188)
Last 7 days (752)
Last 30 days (2493)
Last 365 days (33890)
2025 (10338)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38398)
2014 (32186)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39236)
Australia (6528)
California (6114)
Canada (1992)
China (524)
Colorado (269)
Connecticut (280)
Delaware (144)
Europe (85713)
Florida (886)
Georgia (204)
Idaho (57)
Illinois (543)
India (25)
Indiana (309)
Iowa (12)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (893)
Massachusetts (4656)
Michigan (218)
Minnesota (391)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (66)
New Jersey (1724)
New Mexico (30)
New York (1723)
North Carolina (1019)
North Dakota (7)
Northern California (2650)
Ohio (202)
Oklahoma (14)
Oregon (38)
Pennsylvania (1358)
Puerto Rico (11)
Rhode Island (33)
South America (1110)
South Carolina (22)
South Dakota (1)
Southern California (2293)
Tennessee (101)
Texas (903)
Utah (180)
Virginia (147)
Washington D.C. (63)
Washington State (567)
West Virginia (3)
Wisconsin (53)
714,058 Results for "harpoon therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Merck today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).
March 11, 2024
·
5 min read
Business
Harpoon Therapeutics Strengthens Leadership Team - December 26, 2023
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer.
December 26, 2023
·
5 min read
Biotech Bay
Harpoon Therapeutics Announces Up to $150 Million Private Placement
Harpoon Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million.
October 23, 2023
·
5 min read
Biotech Bay
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
Harpoon Therapeutics, Inc. today announced that management will participate in two upcoming investor conferences.
August 3, 2023
·
1 min read
Business
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.
September 13, 2023
·
4 min read
Business
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
November 9, 2023
·
10 min read
Biotech Bay
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September 2023
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in two upcoming investor conferences in September.
September 5, 2023
·
1 min read
Biotech Bay
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
Harpoon Therapeutics, Inc. announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.
November 2, 2023
·
4 min read
Biotech Bay
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Harpoon Therapeutics, Inc. today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
December 19, 2023
·
4 min read
Drug Development
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
Harpoon Therapeutics, Inc. announced the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma.
September 28, 2023
·
4 min read
1 of 71,406
Next
